People with endometriosis may have seen stories of pain improving on Ozempic, Wegovy or Mounjaro. Here's what the evidence actually shows, who might reasonably consider a GLP-1 medicine, and what to know about safety, contraception and cost in New Zealand.
A landmark 2026 New Zealand study surveyed 657 people with endometriosis and found a median diagnostic delay of ten years — and that nearly half had never heard of the condition when their symptoms began.
Persistent pelvic pain often involves tight pelvic floor muscles and a sensitised nervous system—not just the original condition. Pelvic floor physiotherapy, multidisciplinary care, and sometimes Botox can all play a role in recovery.
If you've ever quietly wondered whether your sex life is "normal," you're not alone. What we see online is not real life—it's curated and performative. Here's an honest look at low libido, painful sex, responsive desire, and the orgasm gap.
New research in The BMJ and JAMA Neurology links long-term Depo-Provera use to a small increase in meningioma risk. This article explains the findings, puts the risk in context, and explores what it means for those using Depo-Provera for contraception or endometriosis management.
One of the most significant yet often unspoken issues I encounter is period poverty. In Aotearoa, a lack of access to affordable period products is not just a financial issue; it’s a public health crisis that affects education, dignity, and well-being.
For the first time in nine years, there’s a new medical treatment available in New Zealand. Ryeqo (relugolix, estradiol, norethisterone acetate) is now registered for adults of reproductive age who have tried other medical or surgical treatments for their endometriosis.
